Mitsubishi Tanabe Pharma Canada

What Mitsubishi Tanabe Pharma Canada does

Mitsubishi Tanabe Pharma Canada, now legally operating as Shionogi Canada Inc., is a wholly-owned Canadian subsidiary of Japanese pharmaceutical company Shionogi & Co., Ltd. Headquartered in Toronto, Ontario, the entity was established through Shionogi's 2022 acquisition of Tanabe Pharma Canada and operates with a small team of 9 employees focused on commercializing specialty pharmaceutical products in the Canadian market.

The company's core offering is RADICAVA® (edaravone), an approved treatment for Amyotrophic Lateral Sclerosis (ALS), available in both intravenous and oral suspension formulations. These two branded products constitute the entirety of the company's product portfolio. Distribution operates through a prescription-based model targeting ALS patients via healthcare providers, supported by a dedicated Patient Support Program (PSP) managed in partnership with Innomar Strategies, which handles patient access logistics, reimbursement support, and inquiries.

From a revenue mechanics standpoint, Shionogi Canada functions as a sales-and-distribution entity for the Canadian market, generating revenue through pharmaceutical product sales of RADICAVA®. There are no own-developed technology platforms, manufacturing operations, or R&D activities disclosed at the Canadian subsidiary level. The business model is essentially a specialty single-product commercialization franchise inherited from Tanabe Pharma Canada and retained post-acquisition to ensure continuity of supply for the Canadian ALS community.

Name

Mitsubishi Tanabe Pharma Canada

Legal name

Shionogi Canada Inc.

Website

https://mt-pharma-ca.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Shionogi Canada Inc. (formerly Mitsubishi Tanabe Pharma Canada) is a Toronto-based subsidiary of Japan's Shionogi & Co., Ltd., distributing RADICAVA® (edaravone) for ALS treatment to Canadian patients via a Patient Support Program managed by Innomar Strategies.

Ownership category

akta.pro rank

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Pharmaceutical Product Sales: Sale of RADICAVA® (edaravone) for the treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada. Revenue generated through prescription-based pharmaceutical product distribution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Shionogi Canada Inc. (formerly Tanabe Pharma Canada) sells RADICAVA® (edaravone) and RADICAVA® Oral Suspension, two prescription pharmaceutical formulations indicated for the treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada. The products are accessed by patients through healthcare provider prescriptions and supported by a patient support program (PSP) operated by Innomar Strategies.

Product overview

Shionogi Canada Inc. (formerly Tanabe Pharma Canada) operates as a discovery-based pharmaceutical company committed to identifying unmet needs and developing treatments for challenging human diseases. Following the acquisition of Tanabe Pharma Canada, the company now provides RADICAVA® and RADICAVA® Oral Suspension for ALS patients in Canada. The product portfolio consists of these two branded pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Products and services

• RADICAVA® RADICAVA® (edaravone) is a prescription medication for the treatment of Amyotrophic Lateral Sclerosis (ALS), provided by Shionogi Canada Inc. (formerly Tanabe Pharma Canada) to ALS patients in Canada through healthcare provider prescriptions and a patient support program.
• RADICAVA® Oral Suspension RADICAVA® Oral Suspension is an oral suspension formulation of edaravone for the treatment of ALS, offered in Canada by Shionogi Canada Inc. (formerly Tanabe Pharma Canada) with continued patient support program access via Innomar Strategies.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Innomar StrategiescoreImplementation/ SI/ Consulting PartnerInnomar Strategies manages the patient support program (PSP) for RADICAVA® in Canada. They provide operational support for patient access, including handling inquiries at 1-833-211-6878 and [email protected]. This partnership ensures continued availability and support for ALS patients in Canada following the acquisition of Tanabe Pharma Canada.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Biogen Canada: Biogen is a major neurology-focused pharmaceutical company with a Canadian presence. It markets Spinraza (nusinersen) for SMA and has been active in ALS/neurodegenerative disease, making it a direct competitor in the Canadian specialty neurology space.
• Amylyx Pharmaceuticals: Amylyx developed AMX0035 (Relyvrio), an approved ALS therapy that directly competes with RADICAVA® in the same indication and is pursuing Canadian regulatory access, making it a head-to-head ALS competitor.

Broad incumbents

• Shionogi & Co., Ltd. (Parent): The Japanese parent company that owns this Canadian subsidiary. Directly comparable as the originator/acquirer of the RADICAVA asset and the strategic decision-maker for the Canadian operations and pipeline.
• Sanofi Canada: Sanofi operates a Canadian pharmaceutical subsidiary with neurology and rare disease exposure (e.g., Genzyme heritage). Comparable as a multinational pharma with Canadian distribution infrastructure for high-need therapies.
• Mitsubishi Tanabe Pharma Corporation (Japan): The originator of edaravone (RADICAVA) and historically the parent entity before Shionogi's acquisition of Tanabe Pharma Canada. It is highly comparable as the source innovator and global distributor of the same molecule.
• Astellas Pharma Canada: Japanese-headquartered pharma with a Canadian affiliate focused on specialty therapeutics. Comparable as a fellow Japanese pharma operating a Canadian commercial entity for branded specialty products.
• Bausch Health (Canada): A large Canadian-headquartered pharmaceutical company with a broad specialty pharma portfolio in Canada. Comparable as a domestic commercial vehicle for branded pharmaceutical products.

Regional players

• Knight Therapeutics: A Canadian specialty pharmaceutical company that in-licenses and commercializes innovative therapies in Canada and select emerging markets. Comparable as a Canadian platform for branded specialty pharma commercialization.

Emerging players

• Ionis Pharmaceuticals: Ionis develops antisense oligonucleotide therapies for neurological diseases, including ALS (e.g., tofersen collaboration with Biogen). It represents an emerging mechanistic competitor in the ALS treatment space.

Others

• Innomar Strategies: Canada's leading specialty pharma services provider and the operator of the RADICAVA® Patient Support Program. Comparable as the distribution/access infrastructure partner, adjacent but not a direct competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/mtp-ca

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mitsubishi Tanabe Pharma Canada